



BEXIMCO PHARMACEUTICALS LTD.

10 July 2007

Beximco Pharma launches high-tech Glyceryl Trinitrate Spray for heart patients

Beximco Pharmaceuticals Ltd. (BPL), the leading-edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh has recently introduced Nitrosol[®], an advanced propellant-driven life saving Glyceryl Trinitrate (GTN) Spray in Bangladesh, a company statement said today.

GTN is considered as a standard therapy for immediate management of acute coronary syndrome and for faster onset of action & convenience, 'Spray' form of this product is invariably the preferred choice to doctors for relieving angina attacks.

The Company statement said that, conventional GTN Spray products available in Bangladesh use air-activated pump spray technology, which may not deliver the medication accurately in each spray and may not remain stable over a long period of time. Nitrosol[®], Beximco's GTN brand, utilizes advanced propellant-driven aerosol spray technique to overcome these shortcomings of conventional sprays. Ozone benign HFA (Hydrofluoroalkane) based Nitrosol[®] spray is also supplied in containers with inseparable actuator parts and together they keep the product free from leaking or air contamination ensuring precise delivery of specified amount of GTN in each puff. BPL has developed this product in collaboration with Europe's one of leading pharmaceutical formulation development companies.

Beximco Pharma Chief Executive Officer Mr. Nazmul Hassan added, *"From the very inception, BPL has always focused on introducing technology driven pharmaceutical products in Bangladesh. For example, in recent years BPL has converted its CFC-based inhalers to advanced ozone benign HFA based inhalers as the first and only company in Bangladesh. BPL is also the first company to introduce Anti-HIV drugs. I strongly believe that the introduction of Nitrosol[®] is in line with this inherent spirit of BPL and we will always endeavour to pioneer in introducing advanced technology driven pharmaceuticals in future."*

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. BPL operates from a 20 acre site in Dhaka and currently employs over 2,300 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Pakistan, Nepal, Bhutan and Myanmar and in other markets overseas, principally in East Africa and South East Asia, including Singapore.